Sweden
· Delayed Price · Currency is SEK Enorama Pharma AB Statistics
Total Valuation
Enorama Pharma AB has a market cap or net worth of SEK 290.88 million. The enterprise value is 273.87 million.
| Market Cap | 290.88M |
| Enterprise Value | 273.87M |
Important Dates
The next estimated earnings date is Friday, November 15, 2024.
| Earnings Date | Nov 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Enorama Pharma AB has 60.47 million shares outstanding. The number of shares has increased by 7.95% in one year.
| Shares Outstanding | 60.47M |
| Shares Change (YoY) | +7.95% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 1.52% |
| Owned by Institutions (%) | 1.78% |
| Float | 2.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 33.61 |
| PB Ratio | 7.51 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.61 |
| EV / Sales | 46.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.74, with a Debt / Equity ratio of 0.95.
| Current Ratio | 2.74 |
| Quick Ratio | 1.89 |
| Debt / Equity | 0.95 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -56.21 |
Financial Efficiency
Return on equity (ROE) is -160.87% and return on invested capital (ROIC) is -94.75%.
| Return on Equity (ROE) | -160.87% |
| Return on Assets (ROA) | -59.86% |
| Return on Capital (ROIC) | -94.75% |
| Revenue Per Employee | 1.17M |
| Profits Per Employee | -8.28M |
| Employee Count | 5 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 1.20 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +56.17% in the last 52 weeks. The beta is 1.48, so Enorama Pharma AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.48 |
| 52-Week Price Change | +56.17% |
| 50-Day Moving Average | 4.76 |
| 200-Day Moving Average | 3.82 |
| Relative Strength Index (RSI) | 42.73 |
| Average Volume (20 Days) | 51,010 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Enorama Pharma AB had revenue of SEK 5.87 million and -41.41 million in losses. Loss per share was -1.01.
| Revenue | 5.87M |
| Gross Profit | -1.92M |
| Operating Income | -39.80M |
| Pretax Income | -41.41M |
| Net Income | -41.41M |
| EBITDA | -39.21M |
| EBIT | -39.80M |
| Loss Per Share | -1.01 |
Balance Sheet
The company has 17.38 million in cash and 368,000 in debt, giving a net cash position of 17.01 million or 0.28 per share.
| Cash & Cash Equivalents | 17.38M |
| Total Debt | 368,000 |
| Net Cash | 17.01M |
| Net Cash Per Share | 0.28 |
| Equity (Book Value) | 38.75M |
| Book Value Per Share | 0.64 |
| Working Capital | 19.11M |
Cash Flow
| Operating Cash Flow | -49.04M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | -32.71% |
| Operating Margin | -678.09% |
| Pretax Margin | -705.54% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Enorama Pharma AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.95% |
| Shareholder Yield | -7.95% |
| Earnings Yield | -20.99% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |